HWM
BXRX

HighMark Wealth Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

HighMark Wealth Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$1.31K – 498
2021
Q1 		$1K Buy
+1
New +$2K ﹤0.01% 472

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

HighMark Wealth Management's BXRX Position: Q2 2021 in Review

HighMark Wealth Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2021, closing a stake of 1 share — an estimated $1.31K sold.

HighMark Wealth Management first reported a position in BXRX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 31 funds tracked by Wall St. Rank hold BXRX as of Q2 2021.

  • HighMark Wealth Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • HighMark Wealth Management sold 1 Baudax Bio, Inc. Common Stock share in Q2 2021, an estimated $1.31K.
  • HighMark Wealth Management first reported a position in Baudax Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • HighMark Wealth Management's Baudax Bio, Inc. Common Stock position peaked at $1K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2021.

Based on HighMark Wealth Management's 13F filing for Q2 2021, filed 2 Aug 2021.